I consider the CMA to be a problem: it is a problem with respect to pricing negotiations, partner negotiations, other regulatory venues and influence and marketing and sales. So, if this is not a full MA then it is (in my view) a huge management failure. A huge failure that was completely avoidable. No other management team that I know of would have failed to run the confirmatory trial immediately. The result is suboptimal outcome.
Now if full MA is granted then I agree that CM et al gets away with one. But, otherwise, the shorts will have a field day with CMA or outright rejection. I do not think there will be much share price appreciation if CMA is the outcome.
Market Data 
Markets 
AI
